Active · per the CBE, 16 September 2026

EUROPHARMEDTECH

BE0685431593

Rechtspersoon Private limited company 1 establishment

EUROPHARMEDTECH is a research organisation in Ganshoren. Private Limited, started on 28 November 2017, 1 establishment.

Keizer Karellaan 400 box 7, 1083 Ganshoren

Behind the company: Arlette Chaerels, Marc Czarka.

Active for

8 year, 9 months

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

  • Negative equity NBB

    More debt than assets in 1 of the last 4 fiscal years.

  • Two loss years in a row NBB

    Negative result in 2024 and 2025.

  • Tight liquidity NBB

    Cash and receivables cover 61 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

EUROPHARMEDTECH from Ganshoren, company number BE0685431593, closed financial year 2025 with a result of € -69,941 after tax. For that financial year EUROPHARMEDTECH recorded a gross margin of € -5,941 and equity of € -28,814. Compared with financial year 2024, the result moved from € -53,223 to € -69,941. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Caution

€ -28,814

▼ € 69,941 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -69,941

▼ 31 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 194

▼ 98% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -47,414.

People and assets in 2025

Full-time equivalents

1.2

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 57,623

▲ 5% vs 2024

€ 48,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 3,683

▼ 45% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 668

▼ 51% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 31,471

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 14,338

▼ 20% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
2022202320242025Change 2024 → 2025
Gross margin € 123,995 € 178,395 € 10,453 € -5,941 ▼ € 16,394
Profit after taxes € 42,597 € 75,401 € -53,223 € -69,941 ▼ € 16,718
Equity € 18,949 € 94,350 € 41,127 € -28,814 ▼ € 69,941
Total debts € 91,604 € 85,109 € 52,572 € 83,773 ▲ 59%
Cash € 19,528 € 74,517 € 7,825 € 194 ▼ 98%
Retained profit € 349 € 75,750 € 22,527 € -47,414 ▼ € 69,941
Dividend € 27,000 € 0 € 0 € 0
Bank debt € 0 € 0 € 1,372 € 668 ▼ 51%
Balance sheet total € 110,553 € 179,459 € 93,699 € 54,960 ▼ 41%
Employees (FTE) 1.1 1.2 1.2 1.2

Key figures of EUROPHARMEDTECH, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to EUROPHARMEDTECH?

What happened at EUROPHARMEDTECH in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • New annual accounts for financial year 2025: loss of € 69,941. filed late Source: NBB ↗
  • New establishment in Ganshoren. KBO
  • Start of the company according to the CBE. KBO

In short

From € 42,597 profit in 2022 to € 69,941 loss in 2025.

Paid € 42,675 in corporate taxes since 2022.

Best year ever: 2023, with € 75,401 profit.

On average € 8,700 of value added per employee in 2024.

Original PDFs at the National Bank ↗

A new publication or filing at EUROPHARMEDTECH? We notify you, reason included.

Follow EUROPHARMEDTECH

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

  1. Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
  2. We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
  3. In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Yes, I want that
See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies
  • De Lijn 8 June 2026 New annual account 2025

    filed on 8 June 2026

    What was left

    € 20 k ▼ 91%

    Money in the bank

    € 178 k ▼ 98%

    Open the dossier →

  • NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
  • bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Real filings at the National Bank

Management

Arlette Chaerels Marc Czarka
EUROPHARMEDTECH
AXESSIMMO
HEALTHCARE MARKET AUTHORIZATION AND ACCESS ASSOCIATES

Behind EUROPHARMEDTECH are Arlette Chaerels and Marc Czarka. Marc Czarka is also behind AXESSIMMO and HEALTHCARE MARKET AUTHORIZATION AND ACCESS ASSOCIATES.

See the full network in the app

Directors

According to the 2025 annual accounts

Arlette Chaerels

Director

Marc Czarka

Director

Also active at: AXESSIMMO, HEALTHCARE MARKET AUTHORIZATION AND ACCESS ASSOCIATES

Establishments

Establishment units

Physical locations of this company

Registered office

Keizer Karellaan 400 box 7

1083 Ganshoren

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

AXESSIMMO same network

€ -2,601 gross margin · 2025

CLEVAIR

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number
0685.431.593
VAT number
BE 0685.431.593
Registered office
Keizer Karellaan 400 bus 7, 1083 Ganshoren
Names & denominations
EUROPHARMEDTECH · EPMT
Enterprise type
Rechtspersoon
Legal form
Private limited company
Legal situation
Normale toestand
Start date
28 November 2017
Peppol
Active · Active since 22 Jul 2025
Activities · NACE

Speur- en ontwikkelingswerk op biotechnologisch gebied

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten

Activiteiten van adviesbureaus op het gebied van public relations en communicatie

Overige diensten op het gebied van informatietechnologie en computer

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Adviesbureaus op het gebied van public relations en communicatie

View on CBE Public ↗ Annual accounts (NBB) ↗

Frequently asked questions

What does EUROPHARMEDTECH do?
EUROPHARMEDTECH is a research organisation in Ganshoren. Private Limited, started on 28 November 2017, 1 establishment.
What is the address of EUROPHARMEDTECH?
The registered office of EUROPHARMEDTECH is located at Keizer Karellaan 400 box 7, 1083 Ganshoren.
Is EUROPHARMEDTECH still active?
Yes. According to the CBE (16 September 2026) EUROPHARMEDTECH is active, legal situation “Normale toestand”, started on 28 November 2017.
Is EUROPHARMEDTECH registered on Peppol?
Yes, EUROPHARMEDTECH is registered on the Peppol network with ID 0208:0685431593.
What is the enterprise number of EUROPHARMEDTECH?
The enterprise number of EUROPHARMEDTECH is BE0685431593.
When was EUROPHARMEDTECH founded?
EUROPHARMEDTECH was founded on 28 November 2017.